Company Filing History:
Years Active: 2012-2013
Title: Innovations of Priit Kogerman in Angiogenesis Inhibition
Introduction
Priit Kogerman is a notable inventor based in Tabasalu, Estonia. He has made significant contributions to the field of medical treatments, particularly in the inhibition of angiogenesis and endothelial cell proliferation. With a total of 2 patents, Kogerman's work focuses on innovative methods and pharmaceutical compositions that have the potential to impact therapeutic treatments.
Latest Patents
Kogerman's latest patents include groundbreaking inventions aimed at controlling angiogenesis. The first patent describes methods of using vimentin to inhibit angiogenesis and endothelial cell proliferation. This invention relates to a treatment method that involves administering an effective amount of vimentin or its derivatives to a subject in need. The patent also covers a pharmaceutical composition and a medicament that utilize vimentin, providing a means to control angiogenesis and endothelial cell proliferation.
The second patent introduces a drug for treating conditions related to the inhibition of angiogenesis and/or endothelial cell proliferation. This invention highlights the use of soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD), which has been shown to inhibit angiogenesis in vivo in chick and mouse models. The anti-angiogenic effect of CD44HABD is notable for being independent of hyaluronic acid binding, as non-HA-binding mutants still exhibit anti-angiogenic properties. This patent also discusses methods for screening new drug targets using CD44 recombinant proteins and their analogues.
Career Highlights
Kogerman's career is marked by his dedication to advancing medical science through innovative research. His work has led to the development of novel therapeutic approaches that address critical health issues related to angiogenesis. His contributions are recognized within the scientific community, and his patents reflect his commitment to improving patient outcomes.
Collaborations
Kogerman has collaborated with esteemed colleagues such as Taavi Pall and Staffan Stromblad. These partnerships have fostered a collaborative environment that enhances the research and development of innovative medical solutions.
Conclusion
Priit Kogerman's work in the field of angiogenesis inhibition showcases his innovative spirit and dedication to medical advancements. His patents represent significant strides in therapeutic treatments, offering hope for improved health outcomes.